Drug Approval | March 31, 2026
ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
The decision is based on the phase 3 DESTINY-Breast11 trial
The decision is based on the phase 3 DESTINY-Breast11 trial
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
Under the agreement, healthcare professionals in the country will gain access to C2N’s PrecivityAD2 blood test
Germany will be the first launch market
Swayam is designed to support elderly patients and their families with seamless access to coordinated medical care
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
